IVA · Inventiva

The thesis

Inventiva's American depositary shares are more likely to lag the S&P 500 over the next three months. The company has one asset, lanifibranor, and its funding is conditional, so the shares carry the full risk of a single trial result. The fourth-quarter 2026 topline from the NATiV3 Phase 3 trial in MASH (metabolic dysfunction-associated steatohepatitis, a fatty-liver disease) settles the call.

The shares closed at $3.88 on 12 November 2026, 46.8% below the 52-week intraday high of $7.29 on 26 January 2026. They are up from the 52-week closing low of $2.87 on 13 October 2026. The three-month change is −15.7%. The 50-day average of closes is $3.66 and the 200-day average is $4.75, both as of 12 November 2026.

Inventiva's latest stated guidance, in its 6 October 2026 release, is topline in the fourth quarter of 2026. As of 13 November 2026, a search of company announcements shows no result and no announced date. Three lanifibranor posters at the AASLD (American Association for the Study of Liver Diseases) meeting ran 5 November to 9 November 2026 and left the timeline unchanged. HC Wainwright & Co. kept its Buy rating but lowered its price target to $14 on 5 November 2026.

Bullish and bearish views on Inventiva S.A.

The bull case on Inventiva S.A. (IVA), in brief: trial treatment is finished. The bear case: funding is conditional.

Bull case

• Trial treatment is finished. Inventiva announced that the last patient completed the 72-week NATiV3 visit on 2 September 2026. Its 28 September 2026 and 6 October 2026 releases kept the fourth-quarter 2026 topline guidance.
• Analyst targets sit far above the price. Piper Sandler maintained Buy with a $26 target on 24 October 2026, and HC Wainwright maintained Buy with a $14 target on 5 November 2026 (Benzinga headlines). Both are well above the $3.88 close of 12 November 2026.
• Cash covers the near term. Cash and equivalents were €166.1 million and short-term deposits €67.8 million at 30 June 2026 (Inventiva half-year release, 28 September 2026). Management guides the runway to the end of the second quarter of 2027.
• The trial is large and the drug has regulatory support. NATiV3 enrolled 1,009 adults in its main cohort and 410 in an exploratory cohort, per company announcements. The FDA has granted lanifibranor Breakthrough Therapy and Fast Track designations, and Inventiva plans a regulatory filing in the first half of 2027 if results are favourable.

Bear case

• Funding is conditional. The 28 September 2026 release states current cash does not cover the next twelve months of planned operations. A runway to the first quarter of 2028 needs the roughly €55 million Tranche C debt and full exercise of the Tranche 3 warrants.
• One broker cut its target. HC Wainwright lowered its price target to $14 on 5 November 2026 (Benzinga headline).
• There is almost no revenue. First-half 2026 revenue was €20,000 against €4.5 million in the first half of 2025, and the net loss was €69.5 million (Inventiva, 28 September 2026).
• One asset carries the company. A miss on the fibrosis endpoint leaves no second program to hold the value.

Price setup

The shares closed at $3.88 on 12 November 2026, up from $3.63 on 5 November 2026 and from the $2.87 closing low of 13 October 2026. The last close sits above the 50-day average of $3.66 and below the 200-day average of $4.75. The 52-week intraday high of $7.29 on 26 January 2026 is the reference level far overhead.

The topline has no announced date, so the shares can move on a date announcement as well as on the data. The $2.87 close of 13 October 2026 is the nearest low below. The shares are dual-listed on Euronext Paris and Nasdaq, so euro-dollar moves and the Paris session also affect the US price. Inventiva is a foreign private issuer and files no Form 4 insider reports, so US insider screens are blank by structure.

Catalysts ahead

• ~31 December 2026 (est.): NATiV3 Phase 3 topline for lanifibranor in MASH, guided to the fourth quarter of 2026 with no announced date. One result decides the value of a single-asset company and the regulatory filing planned for the first half of 2027.
• ~31 December 2026 (est.): Possible draw of the roughly €55 million Tranche C debt. A draw would move the guided runway from the end of the second quarter of 2027 towards the first quarter of 2028.

What would change the view

A daily close above $4.77, just over the 200-day moving average, which would show the shares leading the S&P 500. A positive NATiV3 topline that meets the fibrosis endpoint would also show the shares leading.

What it trades with

Inventiva trades on its own binary event, not on a sector basket. The shares can move with other small-cap MASH and liver-disease developers on read-through news, and with broad small-cap biotech risk appetite. The euro-dollar rate and the Euronext Paris session affect the US-listed shares.